Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
| ▸ | GRK5 | P34947 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232747 | 0.76 | SLC18A3 (0.46) | TNKSTNKS2 | |
| SCHEMBL2028396 | 0.72 | ADH5 (0.32) | — | |
| SCHEMBL13411813 | 0.70 | ADH5 (0.36) | — | |
| SCHEMBL5205994 | 0.68 | CCNB2 (0.41) | GSK3BCDK5KMT2A | |
| SCHEMBL6074332 | 0.68 | ACHE (0.33) | MAPTTNKSTNKS2 | |
| SCHEMBL2150278 | 0.68 | ESR2 (0.78) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2150282 | 0.68 | ESR2 (0.78) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7004274 | 0.68 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3703094 | 0.68 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2047764 | 0.68 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765676-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2014-07-01 | — | — | US | claimed |
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-05-17 | — | — | US | claimed |
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | claimed |
| US-8765676-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2014-07-01 | — | — | US | disclosed |
| US-8765676-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2014-07-01 | — | — | US | disclosed |
| US-8765676-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2014-07-01 | — | — | US | disclosed |
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-05-17 | — | — | US | disclosed |
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-05-17 | — | — | US | disclosed |
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-05-17 | — | — | US | disclosed |
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | CASR, SARAF, ORAI1 | ESR2 974/4885NOTUM 2931/4885PDE4A 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.